title: Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis.
abstract: Alveolar macrophages are major contributors to lung innate immunity. Although alveolar macrophages from cystic fibrosis (CF) transmembrane conductance regulator(-/-) mice have impaired function, no study has investigated primary alveolar macrophages in adults with CF. CF patients have low levels of insulin-like growth factor 1 (IGF-1), and our prior studies demonstrate a relationship between IGF-1 and macrophage function. We hypothesize that reduced IGF-1 in CF leads to impaired alveolar macrophage function and chronic infections. Serum and bronchoalveolar lavage (BAL) samples were obtained from eight CF subjects and eight healthy subjects. Macrophages were isolated from BAL fluid. We measured the ability of alveolar macrophages to kill Pseudomonas aeruginosa. Subsequently, macrophages were incubated with IGF-1 prior to inoculation with bacteria to determine the effect of IGF-1 on bacterial killing. We found a significant decrease in bacterial killing by CF alveolar macrophages compared with control subjects. CF subjects had lower serum and BAL IGF-1 levels compared with healthy control subjects. Exposure to IGF-1 enhanced alveolar macrophage macrophages in both groups. Finally, exposing healthy alveolar macrophages to CF BAL fluid decreased bacterial killing, and this was reversed by the addition of IGF-1, whereas IGF-1 blockade worsened bacterial killing. Our studies demonstrate that alveolar macrophage function is impaired in patients with CF. Reductions in IGF-1 levels in CF contribute to the impaired alveolar macrophage function. Exposure to IGF-1 ex vivo results in improved function of CF alveolar macrophages. Further studies are needed to determine whether alveolar macrophage function can be enhanced in vivo with IGF-1 treatment.
authors.affiliation: Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
authors.forename: Jamie L
authors.initials: JL
authors.lastname: Bessich
authors.forename: Amanda B
authors.initials: AB
authors.lastname: Nymon
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Moulton
authors.forename: Dana
authors.initials: D
authors.lastname: Dorman
authors.forename: Alix
authors.initials: A
authors.lastname: Ashare
mesh_terms: D000328:Adult; D001775:Blood Circulation / Q000235:genetics / Q000276:immunology; D018893:Bronchoalveolar Lavage; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000276:immunology* / Q000382:microbiology / Q000473:pathology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency* / Q000235:genetics / Q000502:physiology*; D016676:Macrophages, Alveolar / Q000276:immunology* / Q000382:microbiology / Q000473:pathology*; D008297:Male; D011552:Pseudomonas Infections / Q000235:genetics / Q000276:immunology / Q000473:pathology; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000276:immunology; D055815:Young Adult
chemical_list: D007334:Insulin-Like Growth Factor I